BVF Inc’s Black Diamond Therapeutics BDTX Stock Holding History

BVF Inc’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-378,788	Closed	-$16M	–	63
2020 Q2	$16M	Hold	378,788	–	–	0.98%	31
2020 Q1	$9.45M	Buy	+378,788	New	+$11.5M	0.88%	29

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc's BDTX Position: Q3 2020 in Review

BVF Inc sold out of Black Diamond Therapeutics (BDTX) in Q3 2020, closing a stake of 378,788 shares — an estimated $16M sold.

BVF Inc first reported a position in BDTX in Q1 2020 and held it in 2 quarters. The position peaked at $16M in Q2 2020. 88 funds tracked by Wall St. Rank hold BDTX as of Q3 2020.

BVF Inc reported no remaining Black Diamond Therapeutics position as of Q3 2020 after selling out during the quarter.
BVF Inc sold 378,788 Black Diamond Therapeutics shares in Q3 2020, an estimated $16M.
BVF Inc first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 2 quarters.
BVF Inc's Black Diamond Therapeutics position peaked at $16M in Q2 2020.
88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2020.

Based on BVF Inc's 13F filing for Q3 2020, filed 13 Nov 2020.